Unveiling Brain Aβ Heterogeneity Through Targeted Proteomic Analysis.

Area of Science:

• Neuroscience
• Biochemistry
• Molecular Biology

Background:

• Alzheimer's disease (AD) is characterized by amyloid-beta (Aβ) deposits in the brain.
• Aβ heterogeneity in deposits suggests enzymatic cleavage, but diverse species remain poorly characterized.

Purpose of the Study:

• To develop and validate a sequential extraction protocol for differential fractionation of soluble and deposited Aβ species.
• To biochemically identify and characterize the molecular diversity of Aβ species in AD brain deposits.

Main Methods:

• Sequential extraction using buffers of increasing stringency (PBS, detergents, formic acid) to isolate Aβ species based on solubility.
• Biochemical identification via Western blot and targeted proteomics (immunoprecipitation coupled with MALDI-ToF mass spectrometry).

Main Results:

• The protocol successfully fractionated soluble and deposited Aβ species.
• Numerous C- and N-terminal truncated Aβ species were identified, beyond Aβ1-40/42.
• Soluble fractions contained predominantly C-terminal cleaved fragments, while N-terminal truncated species required harsher extraction conditions.

Conclusions:

• The developed protocol effectively characterizes Aβ heterogeneity in AD.
• Understanding the diversity and solubility of truncated Aβ species is vital for elucidating AD pathogenesis.
• Truncated Aβ species represent potential novel therapeutic targets for Alzheimer's disease.